Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 319

1.

Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis.

Lomax AJ, McGuire HM, McNeil C, Choi CJ, Hersey P, Karikios D, Shannon K, van Hal S, Carr U, Crotty A, Gupta SK, Hollingsworth J, Kim H, Fazekas de St Groth B, McGill N.

Int J Rheum Dis. 2017 May 8. doi: 10.1111/1756-185X.13076. [Epub ahead of print]

PMID:
28480561
2.

Whole-genome landscapes of major melanoma subtypes.

Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch AM, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, Mularoni L, Wood S, Xu Q, Waddell N, Tembe V, Pupo GM, De Paoli-Iseppi R, Vilain RE, Shang P, Lau LMS, Dagg RA, Schramm SJ, Pritchard A, Dutton-Regester K, Newell F, Fitzgerald A, Shang CA, Grimmond SM, Pickett HA, Yang JY, Stretch JR, Behren A, Kefford RF, Hersey P, Long GV, Cebon J, Shackleton M, Spillane AJ, Saw RPM, López-Bigas N, Pearson JV, Thompson JF, Scolyer RA, Mann GJ.

Nature. 2017 May 11;545(7653):175-180. doi: 10.1038/nature22071. Epub 2017 May 3.

PMID:
28467829
3.

Developing an e-learning resource for nurse airway assistants in the emergency department.

Hersey P, McAleer S.

Br J Nurs. 2017 Feb 23;26(4):217-221. doi: 10.12968/bjon.2017.26.4.217.

PMID:
28230439
4.

Guidelines for the use of platelet transfusions.

Estcourt LJ, Birchall J, Allard S, Bassey SJ, Hersey P, Kerr JP, Mumford AD, Stanworth SJ, Tinegate H; British Committee for Standards in Haematology..

Br J Haematol. 2017 Feb;176(3):365-394. doi: 10.1111/bjh.14423. Epub 2016 Dec 23. No abstract available. Erratum in: Br J Haematol. 2017 Apr;177(1):157.

PMID:
28009056
5.

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.

Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, Joseph R, Gangadhar TC, Dronca R, Patnaik A, Zarour H, Roach C, Toland G, Lunceford JK, Li XN, Emancipator K, Dolled-Filhart M, Kang SP, Ebbinghaus S, Hamid O.

J Clin Oncol. 2016 Dec;34(34):4102-4109. Epub 2016 Oct 31.

PMID:
27863197
6.

Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma.

Jiang CC, Croft A, Tseng HY, Guo ST, Jin L, Hersey P, Zhang XD.

Oncogene. 2016 Nov 17;35(46):6044. doi: 10.1038/onc.2016.144. Epub 2016 Jun 27. No abstract available.

PMID:
27345411
7.

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C.

JAMA. 2016 Apr 19;315(15):1600-9. doi: 10.1001/jama.2016.4059. Erratum in: JAMA. 2016 Jun 14;315(22):2472.

PMID:
27092830
8.

EZH2 as a mediator of treatment resistance in melanoma.

Tiffen JC, Gallagher SJ, Tseng HY, Filipp FV, Fazekas de St. Groth B, Hersey P.

Pigment Cell Melanoma Res. 2016 Sep;29(5):500-7. doi: 10.1111/pcmr.12481. Epub 2016 May 25. Review.

9.

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, Joshua AM, Hersey P, Dronca R, Joseph R, Hille D, Xue D, Li XN, Kang SP, Ebbinghaus S, Perrone A, Wolchok JD.

J Clin Oncol. 2016 May 1;34(13):1510-7. doi: 10.1200/JCO.2015.64.0391. Epub 2016 Mar 7.

11.

Use of the skin pinch test before elective caesarean section.

Hersey P, Gibb S, Thomas S.

Anaesthesia. 2015 Jul;70(7):888-9. doi: 10.1111/anae.13132. No abstract available.

12.

Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy.

Gallagher SJ, Tiffen JC, Hersey P.

Cancers (Basel). 2015 Sep 25;7(4):1959-82. doi: 10.3390/cancers7040870. Review.

13.

Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.

Kakavand H, Vilain RE, Wilmott JS, Burke H, Yearley JH, Thompson JF, Hersey P, Long GV, Scolyer RA.

Mod Pathol. 2015 Dec;28(12):1535-44. doi: 10.1038/modpathol.2015.110. Epub 2015 Sep 25.

14.

Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.

Tiffen JC, Gunatilake D, Gallagher SJ, Gowrishankar K, Heinemann A, Cullinane C, Dutton-Regester K, Pupo GM, Strbenac D, Yang JY, Madore J, Mann GJ, Hayward NK, McArthur GA, Filipp FV, Hersey P.

Oncotarget. 2015 Sep 29;6(29):27023-36. doi: 10.18632/oncotarget.4809.

15.

Genomic Classification of Cutaneous Melanoma.

Cancer Genome Atlas Network..

Cell. 2015 Jun 18;161(7):1681-96. doi: 10.1016/j.cell.2015.05.044.

16.

Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling.

Heinemann A, Cullinane C, De Paoli-Iseppi R, Wilmott JS, Gunatilake D, Madore J, Strbenac D, Yang JY, Gowrishankar K, Tiffen JC, Prinjha RK, Smithers N, McArthur GA, Hersey P, Gallagher SJ.

Oncotarget. 2015 Aug 28;6(25):21507-21.

17.

Pembrolizumab versus Ipilimumab in Advanced Melanoma.

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators..

N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19.

18.

Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB.

Gowrishankar K, Gunatilake D, Gallagher SJ, Tiffen J, Rizos H, Hersey P.

PLoS One. 2015 Apr 6;10(4):e0123410. doi: 10.1371/journal.pone.0123410. eCollection 2015.

19.

Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma.

Wilmott JS, Colebatch AJ, Kakavand H, Shang P, Carlino MS, Thompson JF, Long GV, Scolyer RA, Hersey P.

Mod Pathol. 2015 Jul;28(7):884-94. doi: 10.1038/modpathol.2015.34. Epub 2015 Apr 3.

20.

PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.

Kakavand H, Wilmott JS, Menzies AM, Vilain R, Haydu LE, Yearley JH, Thompson JF, Kefford RF, Hersey P, Long GV, Scolyer RA.

Clin Cancer Res. 2015 Jul 15;21(14):3140-8. doi: 10.1158/1078-0432.CCR-14-2023. Epub 2015 Jan 21.

Supplemental Content

Loading ...
Support Center